Oxford BioMedica Plc (LON:OXB) is a specialist advanced-therapy lentivirus vector biopharma company. It offers vector manufacturing and development services, and also has a proprietary drug pipeline. In addition to LentiVector®
Koovs plc (LON:KOOV) has today announced a major deal with Hindustan Times Media (“HT”). HT is taking a substantial stake in Koovs in exchange for advertising and marketing credit, providing
Evgen Pharma Plc (LON:EVG) is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways
Chamberlin Plc (LON:CMH) remains on track strategically, and the technical problems at the new machine shop are now largely resolved. The group has consequently delivered a significantly improved performance in
Avacta Plc (LON:AVCT) is a pre-clinical biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology, which continues to dominate the
Gateley (Holdings) Plc (LON:GTLY) is a broad-based commercial law and complementary professional services group. It is a leader in the UK mid market, and has seen double digit revenue and
Bionomics Ltd (ASX:BNO) is an Australian biopharmaceutical company specialising in ion channel drug discovery for central nervous system (CNS) disorders such as anxiety and post-traumatic stress disorder (PTSD). BNO also
R.E.A. Holdings Plc (LON:RE.) – the announcement of an improving set of full year results for 2017 was complemented by the announcement that REA Kaltim (REAK) had entered into a
Allergy Therapeutics Plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (SCIT), continues to gain market share
The FY18 results saw adjusted pre-tax profits £1m and statutory profits £2.7m ahead of our expectations. Morses Club (LON:MCL) has focused resources on optimising the potential from the market leader’s
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
